Skip to content

FDA OKs Mylan’s generic version of Biogen MS med Tecfidera

August 18, 2020

The FDA has approved Mylan’s (MYL -0.6%) generic version of Biogen’s (BIIB -0.3%) top seller Tecfidera (dimethyl fumarate).

The agency signed off on the application after a federal judge in West Virginia invalidated a patent on the multiple sclerosis drug. Biogen intends to appeal the decision.

Tecfidera accounted for 32% of Biogen’s Q2 revenue ($1,182M/3,682M).

https://seekingalpha.com/news/3606819-fda-oks-mylans-generic-version-of-biogen-ms-med-tecfidera

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: